BioXcel Therapeutics, Inc. (BTAI)
USD 1.92
(6.08%)
USD 1.92
(6.08%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -155 Million | -135.34 Million | -82.15 Million | -66.35 Million | -27.28 Million | -13.5 Million |
| Net Income | -179.05 Million | -165.75 Million | -106.93 Million | -82.16 Million | -32.96 Million | -19.27 Million |
| Depreciation & Amortization | 318 Thousand | 327 Thousand | 297 Thousand | 188 Thousand | 156 Thousand | 17 Thousand |
| Deferred income taxes | 3.04 Million | - | - | -14.98 Million | -3.45 Million | - |
| Stock-based compensation | 18.61 Million | 17.33 Million | 19.45 Million | 14.61 Million | 3.14 Million | 3.08 Million |
| Change in working capital | 2.01 Million | 10.67 Million | 4.98 Million | 1.02 Million | 2.39 Million | 2.66 Million |
| Other non-cash items | 49 Thousand | 2.07 Million | 46 Thousand | 14.98 Million | 3.45 Million | 3.11 Million |
| Investing Cash Flow | -20 Thousand | -139 Thousand | -445 Thousand | -316 Thousand | -870 Thousand | -340 Thousand |
| Investments in PPE | -20 Thousand | -139 Thousand | -445 Thousand | -316 Thousand | -870 Thousand | -340 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | -870 Thousand | -340 Thousand |
| Financing Cash Flow | 26.52 Million | 96.23 Million | 102.44 Million | 247.35 Million | 18.01 Million | 55.52 Million |
| Debt repayment | - | -95.95 Million | - | - | - | -371 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -27 Thousand | - | - | -9.02 Million | - | - |
| Common Stock Issuance | 26.72 Million | 3.25 | 102.44 Million | 256.38 Million | 17.81 Million | 56.51 Million |
| Other Financing Activities | 26.54 Million | 192.19 Million | 102.44 Million | 256.38 Million | 201 Thousand | -615 Thousand |
| Accounts receivables | 177 Thousand | -248 Thousand | - | - | - | - |
| Accounts payables | -3.21 Million | 13.03 Million | 4.85 Million | 3.03 Million | 3.58 Million | 3.2 Million |
| Inventory | -6000.00 | -1.98 Million | - | - | - | - |
| Other working capital | 5.06 Million | -123 Thousand | 130 Thousand | -2.01 Million | -1.19 Million | -539 Thousand |
| Cash at beginning of period | 193.72 Million | 232.96 Million | 213.11 Million | 32.42 Million | 42.56 Million | 887 Thousand |
| Cash at end of period | 65.22 Million | 193.72 Million | 232.96 Million | 213.11 Million | 32.42 Million | 42.56 Million |
| Capital Expenditure | -20 Thousand | -139 Thousand | -445 Thousand | -316 Thousand | -870 Thousand | -340 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -128.5 Million | -39.24 Million | 19.84 Million | 180.69 Million | -10.13 Million | 41.67 Million |
| Free Cash Flow | -155.02 Million | -135.48 Million | -82.59 Million | -66.66 Million | -28.15 Million | -13.84 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -8.29 Million | -26.79 Million | -22.25 Million | -179.05 Million | -50.48 Million | -53.51 Million |
| Depreciation & Amortization | 77 Thousand | 78 Thousand | 78 Thousand | 318 Thousand | 79 Thousand | 81 Thousand |
| Deferred income taxes | - | - | -15.38 Million | 3.04 Million | 1000.00 | -546 Thousand |
| Stock-based compensation | 1.05 Million | 3.43 Million | 3.59 Million | 18.61 Million | 4.01 Million | 6.12 Million |
| Change in working capital | -5.42 Million | 4.27 Million | -9.2 Million | 2.01 Million | 8.01 Million | 8.88 Million |
| Other non-cash items | -4.54 Million | 822 Thousand | 16.29 Million | 49 Thousand | 789 Thousand | 761 Thousand |
| Investing Cash Flow | - | - | - | -20 Thousand | - | -20 Thousand |
| Investments in PPE | - | - | - | -20 Thousand | - | -20 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 5.3 Million | 26.62 Million | 2.12 Million | 26.52 Million | - | 250 Thousand |
| Debt repayment | - | - | -237 Thousand | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -8000.00 | - | 27 Thousand | -27 Thousand | - | - |
| Common Stock Issuance | 5.31 Million | 26.62 Million | 2.3 Million | 26.72 Million | - | 250 Thousand |
| Other Financing Activities | -8000.00 | -117 Thousand | 2.12 Million | 26.54 Million | - | 250 Thousand |
| Accounts receivables | -434 Thousand | -307 Thousand | 664 Thousand | 177 Thousand | -304 Thousand | -148 Thousand |
| Accounts payables | -4.16 Million | 4.82 Million | -12.31 Million | -3.21 Million | 7.25 Million | 6.49 Million |
| Inventory | -241 Thousand | -448 Thousand | 27 Thousand | -6000.00 | -93 Thousand | 27 Thousand |
| Other working capital | -584 Thousand | 199 Thousand | 2.42 Million | 5.06 Million | 1.16 Million | 2.51 Million |
| Cash at beginning of period | 74.14 Million | 65.22 Million | 89.96 Million | 193.72 Million | 127.54 Million | 165.52 Million |
| Cash at end of period | 56.27 Million | 74.14 Million | 65.22 Million | 65.22 Million | 89.96 Million | 127.54 Million |
| Capital Expenditure | - | - | - | -20 Thousand | - | -20 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -17.87 Million | 8.92 Million | -24.74 Million | -128.5 Million | -37.58 Million | -37.97 Million |
| Free Cash Flow | -23.17 Million | -17.7 Million | -26.86 Million | -155.02 Million | -37.58 Million | -38.22 Million |
INDF
477340
SGBLY
4375
ALTG-PA
GNGBY